Vigesaa Kristy A, Downhour Nathan P, Chui Michelle A, Cappellini Linda, Musil John D, McCallian Dennis J
Banner Baywood Medical Center, Mesa, Arizona.
Int J Pharm Compd. 2004 Jul-Aug;8(4):313-9.
The primary purpose of this six-week survey study of women currently taking compounded bioidentical hormone replacement therapy was to determine if compounded bioidentical hormone replacement therapy relieves symptoms of menopause and is well tolerated. The secondary purpose of this study was to compare the symptom relief and tolerability of compounded bioidentical hormone replacement therapy to previously used commercially available products. All strengths and dosage forms of bi-estrogen and tri-estrogen were included, whether used alone or in combination with progesterone, dehydroepiandrosterone or testosterone. The survey instrument consisted of nineteen questions and evaluated the outcomes and side effects for commercially available versus compounded bioidentical hormones. A total of 160 surveys was distributed and 78 were completed. Overall, 57.7% of the women surveyed reported fewer side effects and 71.8% of the women had better relief of menopausal symptoms when using bioidentical hormone replacement therapy. The occurrence and severity of menopausal symptoms decreased significantly after beginning bioidentical hormone replacement therapy. Before treatment, moderate-to-severe symptoms of hot flashes, night sweats, sleep problems, dry skin/hair, vaginal dryness, foggy thinking, mood swings and decrease in sex drive were reported in 52 % to 70% of the women. After initiating treatment the moderate-to-severe range of symptoms dropped to between 4% and 20%. The most commonly reported side effects with bioidentical hormone replacement therapy were weight gain (37.2%), breast tenderness (19.2%) and bloating (23.1%). Weight gain (56.2%), breast tenderness (54.5%), bloating (40%) and mood swings (36.4%) were most commonly seen with commercially available products. Bioidentical hormone replacement relieved the symptoms of menopause and was well tolerated.
这项针对目前正在接受复方生物同源激素替代疗法的女性进行的为期六周的调查研究，其主要目的是确定复方生物同源激素替代疗法是否能缓解更年期症状以及耐受性良好。本研究的次要目的是将复方生物同源激素替代疗法的症状缓解情况和耐受性与先前使用的市售产品进行比较。所有强度和剂型的双雌激素和三雌激素均包括在内，无论其单独使用还是与孕酮、脱氢表雄酮或睾酮联合使用。调查问卷包含19个问题，评估了市售生物同源激素与复方生物同源激素的疗效和副作用。共发放了160份调查问卷，完成了78份。总体而言，57.7%的受访女性报告副作用减少，71.8%的女性在使用生物同源激素替代疗法时更年期症状得到更好缓解。开始生物同源激素替代疗法后，更年期症状的发生率和严重程度显著降低。治疗前，52%至70%的女性报告有中度至重度的潮热、盗汗、睡眠问题、皮肤/头发干燥、阴道干燥、思维模糊及性欲减退症状。开始治疗后，中度至重度症状范围降至4%至20%之间。生物同源激素替代疗法最常报告的副作用是体重增加（37.2%）、乳房压痛（19.2%）和气胀（23.1%）。市售产品最常出现的是体重增加（56.2%）、乳房压痛（5,4.5%）、气胀（40%）和情绪波动（36.4%）。生物同源激素替代疗法缓解了更年期症状且耐受性良好。
